---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-26-000005"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2026-01-21T23:59:59+00:00"
generated_at: "2026-05-16T09:20:46.733660+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AEON shareholders approve PIPE/Daewoong exchange; BPD Type 2a meeting held with FDA

## Summary
- Shareholders approved PIPE financing, Daewoong note exchange, and 2023 incentive plan at special meeting; exchange closed Jan 21.
- Daewoong exchanged $15M senior secured notes for 11.9M shares, 11.2M pre-funded warrants, $1.5M new note, and 8M warrants.
- Second closing of PIPE expected week of Jan 26: 4.6M shares, 6.6M warrants, and up to 6.6M true-up warrants.
- AEON held BPD Type 2a meeting with FDA for ABP-450 biosimilar; awaiting official minutes within ~30 days.
- Fifth amendment to license agreement with Daewoong adjusts termination purchase right based on Daewoong's sale of 50% of its shares.

## SEC filing metadata
- accession: 0001837607-26-000005
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2026-01-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.02, 5.02, 5.07, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000005/0001837607-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000005/aeon-20260121x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-26-000005
- JSON: https://secwatch.observer/filing/0001837607-26-000005.json
- Plain text: https://secwatch.observer/filing/0001837607-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.